All Stories

  1. Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study

    Article • Current Vascular Pharmacology, September 2020, Bentham Science Publishers

    Sandro Mazzaferro, Ludovica Napoleoni

  2. Oxygen Extraction Ratio (OER) as a Measurement of Hemodialysis (HD) Induced Tissue Hypoxia: A Pilot Study

    Article • Scientific Reports, April 2018, Springer Science + Business Media

    Sandro Mazzaferro

  3. Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation

    Article • PLoS ONE, May 2017, PLOS

    Sandro Mazzaferro

  4. A new Hyperphosphatemia Drug

    Article • Giornale di Techniche Nefrologiche e Dialitiche, November 2016, SAGE Publications

    Sandro Mazzaferro

  5. Role of Bariatric Surgery in Chronic Kidney Disease Patients

    Article • Giornale di Techniche Nefrologiche e Dialitiche, October 2016, SAGE Publications

    Sandro Mazzaferro

  6. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement

    Article • Journal of Nephrology, July 2016, Springer Science + Business Media

    Sandro Mazzaferro, Prof Giuseppe Vezzoli, David Goldfarb, Dr Ziya Kirkali

  7. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients

    Article • Clinical Journal of the American Society of Nephrology, May 2016, American Society of Nephrology

    Sandro Mazzaferro

  8. Vitamin D in patients with chronic kidney disease: a position statement of the Working Group “Trace Elements and Mineral Metabolism” of the Italian Society of Nephrology

    Article • Journal of Nephrology, April 2016, Springer Science + Business Media

    Prof Domenico Russo, Sandro Mazzaferro

  9. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?

    Article • Nephrology Dialysis Transplantation, March 2016, Oxford University Press (OUP)

    prof Marc Vervloet, Sandro Mazzaferro

  10. Vitamin D: a dynamic molecule. How relevant might the dynamism for a vitamin be?

    Article • Nephrology Dialysis Transplantation, September 2015, Oxford University Press (OUP)

    Sandro Mazzaferro

  11. Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet)

    Article • Clinical Kidney Journal, July 2015, Oxford University Press (OUP)

    Sandro Mazzaferro

  12. Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?

    Article • BBA Clinical, June 2015, Elsevier

    Sandro Mazzaferro

  13. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

    Article • Nephrology Dialysis Transplantation, March 2015, Oxford University Press (OUP)

    Sandro Mazzaferro, Prof. Carmine Zoccali

  14. Opponent's comments

    Article • Nephrology Dialysis Transplantation, February 2015, Oxford University Press (OUP)

    Sandro Mazzaferro

  15. Pro: Cardiovascular calcifications are clinically relevant

    Article • Nephrology Dialysis Transplantation, February 2015, Oxford University Press (OUP)

    Sandro Mazzaferro

  16. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study

    Article • BMC Nephrology, February 2015, Springer Science + Business Media

    Sandro Mazzaferro

  17. Solubleα-Klotho Serum Levels in Chronic Kidney Disease

    Article • International Journal of Endocrinology, January 2015, Hindawi Publishing Corporation

    Sandro Mazzaferro

  18. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study

    Article • International Journal of Nephrology and Renovascular Disease, December 2014, Taylor & Francis

    Professor piergiorgio Messa, Sandro Mazzaferro

  19. Calcific Uremic Arteriolopathy: A Call for Action

    Article • Seminars in Nephrology, November 2014, Elsevier

    Sandro Mazzaferro

  20. News on Biomarkers in CKD‐MBD

    Article • Seminars in Nephrology, November 2014, Elsevier

    Sandro Mazzaferro

  21. When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease

    Article • Seminars in Nephrology, November 2014, Elsevier

    Sandro Mazzaferro

  22. Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review

    Article • Journal of Nephrology, July 2014, Springer Science + Business Media

    Sandro Mazzaferro

  23. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders

    Article • The Lancet Diabetes & Endocrinology, May 2014, Elsevier

    prof Marc Vervloet, Sandro Mazzaferro

  24. Editorial ( Thematic issue :VITAMIN D THERAPY: AN UPDATE Available Experimental and Clinical Evidences to Select “ Which D for Which Patient”)

    Article • Current Vascular Pharmacology, April 2014, Bentham Science Publishers

    Sandro Mazzaferro

  25. Therapeutic Use of Calcitriol

    Article • Current Vascular Pharmacology, April 2014, Bentham Science Publishers

    Sandro Mazzaferro

  26. Vitamin D Metabolites and/or Analogs: Which D for Which Patient?

    Article • Current Vascular Pharmacology, April 2014, Bentham Science Publishers

    Sandro Mazzaferro

  27. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?

    Article • Nephrology Dialysis Transplantation, February 2014, Oxford University Press (OUP)

    Sandro Mazzaferro

  28. Achievement of NKF/K-DOQI Recommended Target Values for Bone and Mineral Metabolism in Incident Hemodialysis Patients: Results of the FARO-2 Cohort

    Article • Blood Purification, January 2014, Karger Publishers

    Sandro Mazzaferro

  29. Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis

    Article • American Journal of Kidney Diseases, November 2013, Elsevier

    Sandro Mazzaferro

  30. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation

    Article • Nephrology Dialysis Transplantation, March 2013, Oxford University Press (OUP)

    Sandro Mazzaferro

  31. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study

    Article • Journal of Medical Economics, July 2012, Informa Healthcare

    Sandro Mazzaferro

  32. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <=150 pg/mL: results of the Italian FARO Survey

    Article • Nephrology Dialysis Transplantation, April 2012, Oxford University Press (OUP)

    Sandro Mazzaferro

  33. Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23

    Article • Journal of Nephrology, January 2012, Wichtig

    Sandro Mazzaferro

  34. Treatment of Cardiovascular Calcification in Uremia

    Article • Current Vascular Pharmacology, November 2011, Bentham Science Publishers

    Sandro Mazzaferro

  35. Does any therapy exist for vascular calcifications in uremia

    Article • Journal of Nephrology, January 2011, Wichtig

    Sandro Mazzaferro

  36. New insights into the role of calcium-sensing receptor activation

    Article • Journal of Nephrology, January 2011, Wichtig

    Sandro Mazzaferro

  37. Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality

    Article • Blood Purification, January 2011, Karger Publishers

    Sandro Mazzaferro

  38. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey

    Article • Journal of Nephrology, December 2010, Wichtig

    Sandro Mazzaferro

  39. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?

    Article • Nephrology Dialysis Transplantation, November 2010, Oxford University Press (OUP)

    Sandro Mazzaferro

  40. The bone and the kidney

    Article • Archives of Biochemistry and Biophysics, November 2010, Elsevier

    Sandro Mazzaferro

  41. The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease

    Article • Current Vascular Pharmacology, May 2010, Bentham Science Publishers

    Sandro Mazzaferro

  42. Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients

    Article • Nephrology Dialysis Transplantation, April 2009, Oxford University Press (OUP)

    Prof Domenico Russo, Sandro Mazzaferro

  43. Progression of Coronary Artery Calcification in Renal Transplantation and the Role of Secondary Hyperparathyroidism and Inflammation

    Article • Clinical Journal of the American Society of Nephrology, February 2009, American Society of Nephrology

    Sandro Mazzaferro

  44. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQITM ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients

    Article • Nephrology Dialysis Transplantation, May 2008, Oxford University Press (OUP)

    Sandro Mazzaferro

  45. Vascular Calcification and Uremia: What Do We Know?

    Article • American Journal of Nephrology, November 2007, Karger Publishers

    Sandro Mazzaferro

  46. Serum Levels of Calcification Inhibition Proteins and Coronary Artery Calcium Score: Comparison between Transplantation and Dialysis

    Article • American Journal of Nephrology, January 2007, Karger Publishers

    Sandro Mazzaferro

  47. Morphometric X-ray absorptiometry in the assessment of vertebral fractures in renal transplant patients

    Article • Nephrology Dialysis Transplantation, October 2005, Oxford University Press (OUP)

    Sandro Mazzaferro

  48. How Can We Assess Bone Resorption in Uremia?

    Article • Nephron Clinical Practice, December 2004, Karger Publishers

    Sandro Mazzaferro

  49. Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone

    Article • Osteoporosis International, February 2002, Springer Science + Business Media

    Sandro Mazzaferro

  50. Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate

    Article • Histopathology, June 2001, Wiley

    Sandro Mazzaferro

  51. Changes in adrenomedullin plasma concentrations during haemodialysis in patients with chronic renal failure

    Article • Nephrology Dialysis Transplantation, February 1999, Oxford University Press (OUP)

    Sandro Mazzaferro

  52. Prospective Evaluation of Total Parathyroidectomy and Autotransplantation for the Treatment of Secondary Hyperparathyroidism

    Article • Archives of Surgery, January 1999, American Medical Association (AMA)

    Sandro Mazzaferro

  53. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients

    Article • Nephrology Dialysis Transplantation, September 1998, Oxford University Press (OUP)

    Sandro Mazzaferro

  54. Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis

    Article • International Urology and Nephrology, July 1995, Springer Science + Business Media

    Sandro Mazzaferro

  55. Extent of alkaline phosphatase cytochemistry vs. extent of tetracycline fluorescence in the evaluation of histodynamic variables of bone formation

    Article • Bone, May 1995, Elsevier

    Sandro Mazzaferro

  56. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy

    Article • Nephrology Dialysis Transplantation, January 1995, Oxford University Press (OUP)

    Sandro Mazzaferro

  57. Safe Employment of Recombinant Human Erythropoietin in Pregnancy in Two Anuric Patients on Regular Dialysis Treatment

    Article • Renal Failure, January 1995, Taylor & Francis

    Sandro Mazzaferro

  58. ProcoUagen Type 1 C-Terminal Extension Peptide Serum Levels following Parathyroidectomy in Hyperparathyroid Patients

    Article • American Journal of Nephrology, January 1994, Karger Publishers

    Sandro Mazzaferro

  59. Evaluation of osteoblastic activity by morphometric comparison of alkaline phosphatase cytochemistry vs. tetracycline fluorescence

    Article • Bone, May 1993, Elsevier

    Sandro Mazzaferro

  60. Procollagen type 1 C-terminal extension peptide, PTH and 1,25(0H)2D3 in chronic renal failure

    Article • Bone, May 1993, Elsevier

    Sandro Mazzaferro

  61. Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus

    Article • Nephrology Dialysis Transplantation, January 1993, Oxford University Press (OUP)

    Sandro Mazzaferro

  62. Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure

    Article • The Journal of Steroid Biochemistry and Molecular Biology, September 1992, Elsevier

    Sandro Mazzaferro

  63. Calcium density measurement in histological samples of trabecular bone of normal subjects: Relationship with aging

    Article • Archives of Gerontology and Geriatrics, January 1992, Elsevier

    Sandro Mazzaferro

  64. Procollagen Type I C-Terminal Extension Peptide in Predialysis Chronic Renal Failure

    Article • American Journal of Nephrology, January 1992, Karger Publishers

    Sandro Mazzaferro

  65. Autonomic neuropathy and secondary hyperparathyroidism in uremia

    Article • Journal of the Autonomic Nervous System, July 1990, Elsevier

    Sandro Mazzaferro

  66. Autonomic Neuropathy and Secondary Hyperparathyroidism in Uraemia

    Article • Nephrology Dialysis Transplantation, April 1990, Oxford University Press (OUP)

    Sandro Mazzaferro

  67. PIXE technique for calcium analysis of human bone

    Article • Biological Trace Element Research, August 1986, Springer Science + Business Media

    Sandro Mazzaferro

  68. Circannual versus seasonal variations of longitudinally sampled 25-hydroxycholecalciferol serum levels

    Article • Biochemical Medicine, August 1984, Elsevier

    Sandro Mazzaferro